多西他赛新进展进展.pptxVIP

2016ASCO多西他赛研究汇总;目 录;主要研究介绍：乳腺癌;主要研究介绍：前列腺癌;主要研究介绍：肺癌;相关研究详细介绍：乳腺癌;Abstract 1000：早期乳腺癌蒽环类辅助治疗III期试验联合分析的中期结果（USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49[NRG Oncology]）——高危HER2-乳腺癌多西他赛+环磷酰胺（TC）vs 蒽环/紫杉类化疗方案（TaxAC）;br /Joint Analysis of the ABC (Anthracyclines in early Breast Cancer) Trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) Comparing Docetaxel plus Cyclophosphamide (TC) to Anthracycline/Taxane-based Chemotherapy Regimens (TaxAC) in Women with High-risk, HER2 Negative Breast Cancer;Background;Background;Timeline and Accrual of ABC Trials;ABC Trials Schema;Statistical Plan for ABC Trials;Statistical Plan for ABC Trials;Key Eligibility for ABC Trials;ABC Trials Study Population;ABC Trialsbr /Patient Characteristics % all Patients;ABC Trialsbr /Patient Characteristics % all Patients;Results of Interim Analysis of ABC Trials;ABC Trials: Invasive Disease Free Survival;Forest Plot of IDFS By Stratification Variables;Forest Plot of IDFS By Hormone and Nodal Status;ABC Trials: IDFS by Hormone and Nodal Statusbr /Exploratory Analysis ;Slide 17;ABC Trials: First IDFS Events (N);ABC Trials: Overall Survival;Conclusions;ABC Trials: Acknowledgements;;Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide in the treatment of early breast cancer: 10-year survival results from the randomized FinXX trial.br /;Disclosures;Study Background;The FinXX Trial (NCT0114816) ;Current analysis of the trial;Study endpoints ;Main inclusion criteria ;Main exclusion criteria;FinXX design;Adjuvant trastuzumab;Baseline characteristics;Disposition of patients;RFS /OS events1;Recurrence-free survival;Exploratory subgroup analyses for RFS;RFS in biological subgroups;Overall survival;Slide 18;RFS / OS events: Triple-negative BC;Second invasive cancers1;Summary ;Conclusions;Acknowledgements;;PANTHER br /Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuva